

CITATION REPORT

List of articles citing

BRAF mutation in thyroid cancer

DOI: 10.1677/erc.1.0978

Endocrine-Related Cancer, 2005, 12, 245-62.

Source: <https://exaly.com/paper-pdf/39117772/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1026	The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. 2005 , 63, 263-6		35
1025	The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. 2005 , 63, 588-93		191
1024	What's new in general surgery: endocrine surgery. 2005 , 201, 746-53		25
1023	[Pathogenesis of differentiated thyroid cancer (papillary and follicular)]. 2005 , 49, 691-700		7
1022	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 2005 , 90, 5265-9		101
1021	Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?. 2005 , 1, 497-510		17
1020	Unusual thyroid tumors: a review of pathologic and molecular diagnosis. 2005 , 5, 725-34		19
1019	Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. 2005 , 153, 701-9		61
1018	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 2005 , 90, 6373-9		775
1017	CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. 2006 , 16, 633-42		85
1016	RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. 2006 , 155, 645-53		154
1015	Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 2006 , 91, 3667-70		132
1014	Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. <i>Endocrine-Related Cancer</i> , 2006 , 13, 485-95	5.7	47
1013	Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 2006 , 2, 42-52		54
1012	Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. 2006 , 37, 824-30		87
1011	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. 2006 , 37, 781-6		63
1010	Genetic considerations in thyroid cancer. 2006 , 13, 111-8		17

1009	Poorly differentiated and anaplastic thyroid cancer. 2006 , 13, 119-28	144
1008	BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. 2006 , 15, 136-43	122
1007	BRAF mutation in thyroid carcinogenesis and its clinical implications. 2006 , 13, 455-459	2
1006	New molecular targeted therapies in thyroid cancer. 2006 , 17, 869-79	17
1005	Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. 2006 , 13, 228-37	14
1004	Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599Ins)). 2006 , 64, 105-9	70
1003	The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. 2006 , 65, 364-8	200
1002	Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. 2006 , 65, 660-6	158
1001	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. 2006 , 6, 292-306	674
1000	Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. 2006 , 19, 634-40	86
999	High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. 2006 , 126, 2111-8	101
998	Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. 2006 , 25, 4235-40	49
997	Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 2006 , 25, 5467-74	53
996	Pathology and genetics of thyroid carcinoma. 2006 , 94, 662-9	136
995	RET and neuroendocrine tumors. 2006 , 9, 179-92	26
994	Back to the roots: the remarkable RAF oncogene story. 2006 , 63, 1314-30	84
993	Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. 2006 , 203, 715-22	23
992	RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. 2006 , 56, 164-72	64

991	Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. 2006 , 107, 1831-8		107
990	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. 2006 , 119, 2322-9		140
989	Raf kinases: oncogenesis and drug discovery. 2006 , 119, 2261-71		87
988	Selective modulation of protein kinase A I and II reveals distinct roles in thyroid cell gene expression and growth. 2006 , 20, 3196-211		33
987	Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. 2006 , 2, 180-1		25
986	Is BRAF the Achilles' Heel of thyroid cancer?. 2006 , 12, 1661-4		20
985	Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. <i>Endocrine-Related Cancer</i> , 2006 , 13, 455-64	5-7	184
984	Lack of BRAF mutations in hyalinizing trabecular neoplasm. 2006 , 3, 17		18
983	Human melanoma cells express functional receptors for thyroid-stimulating hormone. <i>Endocrine-Related Cancer</i> , 2006 , 13, 1269-77	5-7	25
982	Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. 2006 , 66, 6521-9		112
981	Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. 2006 , 12, 1785-93		122
980	RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. 2006 , 27, 535-60		261
979	The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. 2006 , 95, 1670-7		22
978	BRAF is a therapeutic target in aggressive thyroid carcinoma. 2006 , 12, 1623-9		145
977	Gene therapy for thyroid cancer. 2006 , 1, 367-378		1
976	BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 2007 , 92, 2264-71		94
975	RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 2007 , 67, 381-90		45
974	DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. 2007 , 74, 344-52		22

973	Mechanisms of Disease: molecular genetics of childhood thyroid cancers. 2007 , 3, 422-9		60
972	Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. 2007 , 92, 4686-95		61
971	Incidentally discovered tumors of the endocrine glands. 2007 , 3, 463-74		4
970	Update in thyroidology. 2007 , 92, 3755-61		5
969	High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. 2007 , 92, 2387-90		134
968	Biological agents in head and neck cancer. 2007 , 7, 1643-50		4
967	Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. 2007 , 92, 4712-8		90
966	Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. 2007 , 6, 1070-8		52
965	HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2007 , 14, 445-52	5:7	54
964	New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. <i>Endocrine-Related Cancer</i> , 2007 , 14, 957-77	5:7	71
963	Genetic alterations in thyroid cancer: the role of mouse models. 2007 , 44, 1-14		26
962	The prevalence and prognostic value of BRAF mutation in thyroid cancer. 2007 , 246, 466-70; discussion 470-1		336
961	Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. 2007 , 92, 4766-70		35
960	Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. 2007 , 13, 1341-9		141
959	Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. 2007 , 13, 1140-8		68
958	BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 2007 , 92, 2840-3		290
957	Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. 2007 , 13, 1161-70		317
956	BRAF in papillary thyroid carcinoma of ovary (struma ovarii). 2007 , 31, 1337-43		75

955	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. 2007 , 38, 1810-8	36
954	Hashimoto's thyroiditis: Is the epithelium premalignant?. 2007 , 1299, 281-288	3
953	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. 2007 , 28, 742-62	755
952	Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. 2007 , 97, 818-25	55
951	Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. 2007 , 17, 381-8	58
950	Technology Insight: small, noncoding RNA molecules as tools to study and treat endocrine diseases. 2007 , 3, 827-34	6
949	Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. 2007 , 17, 1109-15	81
948	RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. 2007 , 148, 936-41	176
947	Thyroid cancer molecular signaling pathways and use of targeted therapy. 2007 , 36, 839-53, viii	23
946	Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. 2007 , 6, 21	47
945	Gene methylation in thyroid tumorigenesis. 2007 , 148, 948-53	140
944	Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. 2007 , 17, 289-301	34
943	The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. 2007 , 92, 3511-6	82
942	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 2007 , 92, 4085-90	329
941	ras Mutation in Korean Papillary Thyroid Carcinomas. 2007 , 22, 203	1
940	New drugs in thyroid cancer. 2007 , 51, 857-61	4
939	Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. 2007 , 120, 196-200	39
938	Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. 2007 , 121, 767-75	51

937	BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid . 2007 , 110, 1218-26	73
936	The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. 2007 , 46, 242-8	36
935	Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF. 2007 , 1, 672-80	7
934	Targeting BRAF in thyroid cancer. 2007 , 96, 16-20	82
933	BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. 2007 , 96, 1549-53	41
932	NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. 2007 , 97, 531-8	26
931	Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. 2007 , 20, 779-87	69
930	Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. 2007 , 66, 678-83	134
929	Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. 2007 , 57, 12-20	28
928	Pathway aberrations of murine melanoma cells observed in Paired-End diTag transcriptomes. 2007 , 7, 109	7
927	A break-apart fluorescence in situ hybridization assay for detecting RET translocations in papillary thyroid carcinoma. 2007 , 178, 128-34	7
926	New directions in the treatment of thyroid cancer. 2007 , 205, S45-8	12
925	Hypothyroidism and hyperthyroidism modulates Ras-MAPK intracellular pathway in rat thyroids. 2007 , 31, 174-8	6
924	RET signaling in endocrine tumors: delving deeper into molecular mechanisms. 2007 , 18, 57-67	26
923	Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. 2007 , 18, 163-73	183
922	Molecular biology of thyroid cancer initiation. 2007 , 9, 686-93	16
921	Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. 2008 , 32, 722-8	24
920	K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. 2008 , 14, 267-73	28

919	Controversies in thyroid pathology: the diagnosis of follicular neoplasms. 2008 , 19, 156-65	30
918	Rôle du cytopathologiste dans la prise en charge d'un nodule thyroïdien. 2008 , 2008, 37-44	0
917	Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. 2008 , 113, 247-55	56
916	Evaluation and treatment of thyroid nodules: a clinical guide. 2008 , 75, 299-311	5
915	Thyroid carcinoma: molecular pathways and therapeutic targets. 2008 , 21 Suppl 2, S37-43	281
914	BRAF(E600) in benign and malignant human tumours. 2008 , 27, 877-95	216
913	Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. 2008 , 15, 101-7	29
912	Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. 2008 , 99, 1847-52	15
911	Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. 2008 , 68, 108-16	103
910	BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. 2008 , 68, 618-34	95
909	Recent advances in thyroid cancer. 2008 , 45, 156-250	53
908	Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. 2008 , 7, 89	18
907	Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. 2008 , 8, 83-95	227
906	Molecular pathology of thyroid cancer: diagnostic and clinical implications. 2008 , 22, 955-69	119
905	Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies. 2008 , 659, 109-17	33
904	Clinical implications of BRAF mutation in thyroid carcinoma. 2008 , 19, 138-45	70
903	Anaplastic thyroid cancer. 2008 , 37, 525-38, xi	131
902	BRAF(V600E) mutation and the biology of papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008 , 15, 191-205	5.7 183

901	Clinical impact of molecular analysis on thyroid cancer management. 2008 , 17, 1-35, vii	10
900	Recent advances in molecular biology of thyroid cancer and their clinical implications. 2008 , 41, 1135-46, ix	57
899	Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. 2008 , 68, 6770-8	91
898	Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. 2008 , 14, 342-6	322
897	Phase II trial of sorafenib in advanced thyroid cancer. 2008 , 26, 4714-9	538
896	RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. 2008 , 68, 7176-82	116
895	Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. 2008 , 8, 367-77	106
894	Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. 2008 , 84, 78-82	52
893	RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. 2008 , 8, 625-32	68
892	BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. 2008 , 68, 6145-53	130
891	Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. 2008 , 14, 4908-4914	42
890	Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008 , 15, 183-90	5-7 34
889	MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. 2008 , 93, 1600-8	485
888	Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. 2008 , 93, 278-84	157
887	Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 2008 , 93, 611-8	146
886	Perspectives for improved and more accurate classification of thyroid epithelial tumors. 2008 , 93, 3286-94	34
885	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. 2008 , 93, 3943-9	416
884	Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. 2008 , 17, 118-25	127

883	Gene expression profiles of post-Chernobyl thyroid cancers. 2008 , 15, 440-5	9
882	Recent developments in the clinical application of thyroid cancer biomarkers. 2008 , 20, 13-8	49
881	Multi-targeted approach in the treatment of thyroid cancer. 2008 , 4, 935-47	15
880	Hereditary non-polyposis colorectal cancer is predicted to contribute towards colorectal cancer in young South African blacks. 2009 , 105,	0
879	Thyroid and Parathyroid Glands. 2009 , 563-646	4
878	Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. 2009 , 135, 347-54	13
877	Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. 2009 , 19, 137-41	87
876	BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. 2009 , 161, 467-73	98
875	Genetic-targeted therapy of thyroid cancer: a real promise. 2009 , 19, 805-9	12
874	New therapeutic advances in the management of progressive thyroid cancer. <i>Endocrine-Related Cancer</i> , 2009 , 16, 715-31	5-7 39
873	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 2009 , 161, 923-31	187
872	High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. 2009 , 15, 485-91	96
871	Modeling thyroid cancer in the mouse. 2009 , 41, 488-99	10
870	Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit. 2009 , 94, 4661-4	8
869	Protein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropin. 2009 , 76, 1123-9	23
868	Molecular diagnostics and predictors in thyroid cancer. 2009 , 19, 1351-61	258
867	Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features. <i>Endocrine-Related Cancer</i> , 2009 , 16, 467-81	5-7 14
866	Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change. 2009 , 132, 906-12	17

865	Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. 2009 , 43, 143-55	56
864	A novel HSP90 modulator with selective activity against thyroid cancers in vitro. 2009 , 146, 1196-207	22
863	Personalized medicine: the future is not what it used to be. 2009 , 146, 971-8	4
862	Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). 2009 , 1795, 152-61	29
861	High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. 2009 , 115, 972-80	104
860	RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. 2009 , 48, 975-82	77
859	Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. 2009 , 20, 75-86	208
858	MicroRNA expression profiles in thyroid tumors. 2009 , 20, 85-91	96
857	A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. 2009 , 20, 122-6	65
856	Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. 2009 , 217, 707-15	32
855	Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. 2009 , 70, 139-44	65
854	Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. 2009 , 70, 629-35	28
853	Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. 2009 , 19, 6519-23	24
852	Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. 2009 , 16, 240-5	125
851	A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous, skeletal, and endocrine systems. 2009 , 84, 134-47	47
850	Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer?. 2009 , 5, 1225-9	3
849	A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. 2009 , 19, 837-42	71
848	B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. 2009 , 140, 709-14	16

847	Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. 2009 , 9, 1261-75	6
846	[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. 2009 , 56, 176-86	12
845	PIK3CA alterations in Middle Eastern ovarian cancers. 2009 , 8, 51	33
844	Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. 2009 , 11, 57-65	37
843	Iodine mediated mechanisms and thyroid carcinoma. 2009 , 46, 302-18	26
842	The Role of BRAFV600E Mutation in the Management of Thyroid Papillary Carcinoma. 2009 , 14, 231-235	3
841	Multiple endocrine neoplasia type 2. 2009 , 4, 443-465	2
840	BRAF mutation in papillary thyroid carcinoma: a potential target for therapy?. 2009 , 4, 467-480	
839	BRAF Mutations in Papillary Thyroid Carcinoma. 2010 , 15, 121-125	
838	Oncogenesis and Molecular Targeted Therapy in Thyroid Cancer. 2010 , 87-103	
837	Molecular pathogenesis of follicular cell derived thyroid cancers. 2010 , 8, 186-93	42
836	Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy. 2010 , 148, 654-60; discussion 660	9
835	UbcH10 expression on thyroid fine-needle aspirates. 2010 , 118, 157-65	18
834	BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. 2010 , 127, 2965-73	44
833	Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. 2010 , 56, 632-40	31
832	Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. 2010 , 102, 376-82	92
831	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 2010 , 16, 793-8	382
830	Review of the genetics of thyroid tumours: diagnostic and prognostic implications. 2010 , 80, 33-40	15

829	The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. 2010 , 2, 885-912	37
828	Thyroid cancer: current molecular perspectives. 2010 , 2010, 351679	20
827	Can Review of Sonographic Findings Spare Diagnostic Thyroidectomy in Patients with Thyroid Nodules Suspicious of Follicular Neoplasm Cytologically?. 2010 , 79, 86	
826	Endocrine side effects of broad-acting kinase inhibitors. <i>Endocrine-Related Cancer</i> , 2010 , 17, R233-44	5-7 55
825	BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. 2010 , 163, 659-63	50
824	MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. 2010 , 9, 1968-76	59
823	Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. 2010 , 9, 190-201	22
822	Rapid multiplex real-time PCR by molecular beacons for different BRAF allele detection in papillary thyroid carcinoma. 2010 , 19, 1-8	14
821	Research Highlights. 2010 , 7, 617-619	
820	Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. 2010 , 162, 145-51	85
819	Importance of Hormones and Proteins Determination in the Material Obtained by Fine-Needle Aspiration. 2010 , 29, 237-244	2
818	Recent Developments in the Molecular Biology of the Thyroid. 2010 , 237-260	2
817	Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. 2010 , 16, 778-83	29
816	BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasonographic classification: a potential guide for selection of samples for molecular analysis. 2010 , 20, 273-9	65
815	Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. 2010 , 20, 697-706	230
814	A case of papillary thyroid carcinoma in struma ovarii and review of the literature. 2010 , 2010, 352476	18
813	Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. 2010 , 23, 1201-8	45
812	Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. 2010 , 17, 1839-50	34

811	[BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens]. 2010 , 30, 252-62	5
810	Ultrasound-guided procedures for the office. 2010 , 43, 1241-54, vi	6
809	Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. 2010 , 41, 1299-309	40
808	Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. 2010 , 160, 179-83	20
807	Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. 2010 , 321, 36-43	45
806	Prognostic utility of BRAF mutation in papillary thyroid cancer. 2010 , 321, 86-93	167
805	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. 2010 , 322, 8-28	99
804	Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. 2010 , 322, 29-37	102
803	Multikinase inhibitors in thyroid cancer. 2010 , 46, 1012-8	13
802	Mouse models of endocrine tumours. 2010 , 24, 451-60	4
801	Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction. 2010 , 194, W425-30	26
800	BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. 2010 , 23, 1052-60	38
799	Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca ²⁺ -binding protein S100A6 in papillary thyroid carcinoma. 2010 , 20, 1067-76	26
798	Molecular analysis of thyroid tumors. 2011 , 24 Suppl 2, S34-43	121
797	Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. 2011 , 71, 3863-71	72
796	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. 2011 , 1, 241-253	3
795	Diagnosis and treatment of differentiated thyroid carcinoma. 2011 , 49, 453-62, vi	9
794	Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. 2011 , 21, 119-24	45

793	BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. 2011 , 58, 175-184	6
792	[BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma]. 2011 , 58, 175-84	9
791	BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. 2011 , 5, 277-90	16
790	The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). 2011 , 404, 958-62	41
789	Molecular genetics and diagnosis of thyroid cancer. 2011 , 7, 569-80	632
788	Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment. 2011 , 332, 9-20	11
787	Multikinase inhibitors: a new option for the treatment of thyroid cancer. 2011 , 7, 617-24	102
786	Molecular Biology of Thyroid Cancer. 2011 ,	
785	New treatments and shifting paradigms in differentiated thyroid cancer management. 2011 , 18, 96-103	9
784	The spectrum of papillary thyroid carcinoma variants. 2011 , 18, 90-7	29
783	New targeted therapies for thyroid cancer. 2011 , 12, 626-31	45
782	Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. 2011 , 58, 381-93	28
781	Update on the molecular signature of differentiated thyroid cancer: clinical implications and potential opportunities. 2011 , 6, 819-834	3
780	The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. 2011 , 75, 844-50	24
779	Diagnostic dilemmas of hyalinizing trabecular tumours on fine needle aspiration cytology: a study of seven cases with BRAF mutation analysis. 2011 , 22, 407-13	18
778	Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF β signaling. 2011 , 30, 3153-62	145
777	mTOR signaling in disease. 2011 , 23, 744-55	354
776	Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2011 , 18, 687-97	5.7 62

775	Helix pomatia agglutinin binding glycoproteins in thyroid tumors. 2011 , 35, 2219-27	2
774	Molecular analysis of thyroid tumors. 2011 , 22, 126-33	79
773	Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain. 2011 , 22, 184-9	33
772	Biphasic low-grade nasopharyngeal papillary adenocarcinoma with a prominent spindle cell component: report of a case localized to the posterior nasal septum. 2011 , 5, 306-13	21
771	Partners in crime: the TGF β and MAPK pathways in cancer progression. 2011 , 1, 42	62
770	Apport de la biologie moléculaire en pathologie thyroïdienne. 2011 , 2011, 49-56	1
769	Hyalinizing trabecular adenoma of the thyroid gland. 2011 , 39, 306-10	25
768	Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. 2011 , 16, 296-309	80
767	Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. 2011 , 21, 391-9	28
766	Suitability of animal models for studying radiation-induced thyroid cancer in humans: evidence from nuclear architecture. 2011 , 21, 1331-7	3
765	The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. 2011 , 211, 79-85	22
764	Role of BRAF in thyroid oncogenesis. 2011 , 17, 7511-7	80
763	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. 2011 , 165, 315-22	165
762	BRAFV600E: implications for carcinogenesis and molecular therapy. 2011 , 10, 385-94	291
761	Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. 2011 , 2011, 387062	27
760	The role of epigenetic alterations in papillary thyroid carcinogenesis. 2011 , 2011, 895470	12
759	Targeted treatment of differentiated and medullary thyroid cancer. 2011 , 2011, 102636	3
758	Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?. <i>Endocrine-Related Cancer</i> , 2011 , 18, 579-94 5-7	28

757	Thyroid cancer: pathogenesis and targeted therapy. 2011 , 2, 173-95		48
756	Managing anaplastic thyroid carcinoma. 2011 , 6, 793-809		4
755	Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. 2011 , 96, 658-64		116
754	Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. 2011 , 21, 511-7		19
753	Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. <i>Endocrine-Related Cancer</i> , 2011 , 18, 159-69	5-7	104
752	Recent advances in molecular diagnosis of thyroid cancer. 2011 , 2011, 384213		13
751	BRAFV600E mutation and papillary thyroid cancer: chicken or egg?. 2012 , 97, 2295-8		23
750	Rethinking the role of oncogenes in papillary thyroid cancer initiation. <i>Frontiers in Endocrinology</i> , 2012 , 3, 83	5-7	8
749	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. 2012 , 91, 274-286		207
748	Modifications in the papillary thyroid cancer gene profile over the last 15 years. 2012 , 97, E1758-65		59
747	Thyroid fine needle aspirate: a post-Bethesda update. 2012 , 19, 160-9		18
746	CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. 2012 , 11, 930-41		35
745	BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles. 2012 , 198, 668-74		21
744	Multikinase inhibitors in thyroid cancer. 2012 , 23 Suppl 10, x328-33		1
743	Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. 2012 , 22, 536-41		20
742	Gene of the month: BRAF. 2012 , 65, 986-8		8
741	Follicular adenoma with extensive extracellular mucin deposition: report on two cases. 2012 , 5, 155-62		4
740	New insight into the treatment of advanced differentiated thyroid cancer. 2012 , 2012, 437569		8

739	Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. 2012 , 255, 986-92	31
738	Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. 2012 , 36, 844-50	163
737	Uncommon Cancers of the Thyroid. 2012 , 189-200	
736	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). 2012 , 6, 687-94	20
735	Comparison of the diagnostic accuracy of combined elastosonography and BRAF analysis vs cytology and ultrasonography for thyroid nodule suspected of malignancy. 2012 , 77, 608-14	9
734	Thyroid function: optimizing molecular testing in thyroid nodule cytology. 2012 , 8, 390-1	2
733	Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. 2012 , 25, 1203-11	18
732	Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. 2012 , 14, R103	32
731	Approach to and treatment of differentiated thyroid carcinoma. 2012 , 96, 369-83	52
730	From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012. 2012 , 73, 155-64	14
729	Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. 2012 , 22, 292-8	33
728	Ultrasound-Guided Procedures for the Office. 2012 , 7, 219-228	2
727	New treatment modalities in advanced thyroid cancer. 2012 , 23, 10-18	54
726	Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. 2012 , 203, 436-41	66
725	BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. 2012 , 39, 198-203	44
724	BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. 2012 , 43, 89-95	33
723	Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. 2013 , 35, 1499-506	17
722	Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. 2012 , 12, 224	16

721	Genomic biomarkers for patient selection and stratification: the cancer paradigm. 2012 , 4, 2499-511	7
720	A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. 2012 , 204, 895-900; discussion 900-1	38
719	Emerging therapies for thyroid carcinoma. 2012 , 10, 53-8	5
718	Expression of the ring ligase PRAJA2 in thyroid cancer. 2012 , 97, 4253-9	14
717	Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. 2012 , 97, 3996-4003	71
716	BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. 2012 , 42, 404-10	42
715	Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. 2012 , 29, 3360-6	34
714	Molecular Changes in Radiation Induced Thyroid Carcinomas in Mice. 2012 , 307-316	
713	A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. 2012 , 97, 2333-40	103
712	Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. 2012 , 6, 179	8
711	Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. 2012 , 7, e49192	12
710	Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas. 2012 , 27, 729-35	1
709	Review of Molecular Markers for Thyroid Cancer. 2012 , 35, 3	
708	Emerging role of multikinase inhibitors for refractory thyroid cancer. 2012 , 6, 257-65	9
707	Prevalence of the B Type Raf Kinase V600E Mutation in Cytologically Indeterminate Thyroid Nodules: Correlation with Ultrasonographic and Pathologic Features. 2012 , 66, 17	
706	Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. 2012 , 19, 31-6	40
705	A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. 2012 , 107, 994-1000	76
704	Association between STAT1 activity and BRAF mutations in papillary thyroid carcinomas. 2012 , 106, 719-23	5

703	Novel molecular targeted therapies for refractory thyroid cancer. 2012 , 34, 736-45	19
702	A more sensitive platform for the detection of low-abundance BRAF(V600E) mutations. 2012 , 366, 49-58	10
701	BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. 2012 , 23, 83-93	56
700	Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. 2012 , 18, 449-58	21
699	Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. 2012 , 60, 1052-9	46
698	RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. 2012 , 61, 833-43	37
697	Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation. 2012 , 62, 43-8	14
696	Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. 2012 , 120, 44-51	30
695	Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer. 2012 , 105, 10-4	4
694	Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. 2013 , 132, 738-43	16
693	Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues. 2013 , 32, 13-8	16
692	Diagnostic biomarkers of differentiated thyroid cancer. 2013 , 44, 616-22	26
691	Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. 2013 , 23, 1423-30	83
690	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. 2013 , 309, 1493-501	605
689	Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. 2013 , 23, 1256-62	88
688	Sorafenib and thyroid cancer. 2013 , 27, 615-28	33
687	Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. 2013 , 98, 2834-43	24
686	Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. 2013 , 23, 1525-31	37

685	B-Raf mutation: a key player in molecular biology of cancer. 2013 , 95, 336-42	44
684	Sonographically suspicious thyroid nodules with initially benign cytologic results: the role of a core needle biopsy. 2013 , 23, 703-8	52
683	Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. 2013 , 119, 1495-502	51
682	Thyroid and Parathyroid Tumors. 2013 , 297-361	
681	Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. 2013 , 154, 1255-61; discussion 1261-2	17
680	Molecular pathogenesis and mechanisms of thyroid cancer. 2013 , 13, 184-99	909
679	Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. 2013 , 1, 3	57
678	German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. 2013 , 398, 347-75	152
677	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. 2013 , 98, E364-9	157
676	Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. 2013 , 23, 517-9	17
675	Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. 2013 , 184, 898-906	27
674	Genetic mutations, molecular markers and future directions in research. 2013 , 49, 711-21	6
673	Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. 2013 , 98, E1414-21	66
672	Signaling pathways in follicular cell-derived thyroid carcinomas (review). 2013 , 42, 19-28	23
671	Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. 2013 , 168, 675-81	39
670	Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. 2013 , 23, 1383-9	103
669	Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. 2013 , 23, 50-7	126
668	Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. 2013 , 23, 1416-22	62

667	Advances in management of thyroid cancer. 2013 , 50, 241-89		12
666	Association d'un carcinome papillaire thyroïdien ^ une tuberculose thyroïdienne : ^ propos d'un cas et revue de la littérature. 2013 , 5, 228-231		
665	Diagnosis and management of differentiated thyroid cancer using molecular biology. 2013 , 123, 1059-64		42
664	Central role of RET in thyroid cancer. 2013 , 5, a009233		68
663	Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients. 2013 , 2013, 128735		30
662	A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation. 2013 , 47, 293-8		6
661	Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. 2013 , 25, 224-8		27
660	Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. 2013 , 35, 412-8		23
659	New targeted therapies and other advances in the management of anaplastic thyroid cancer. 2013 , 25, 44-9		16
658	Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. <i>Endocrine-Related Cancer</i> , 2013 , 20, 13-22	5-7	38
657	Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. 2013 , 51, 1673-80		25
656	Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. 2013 , 105, 1617-27		72
655	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. <i>Endocrine-Related Cancer</i> , 2013 , 20, 603-10	5-7	403
654	BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy. 2013 , 114, 1174-82		9
653	That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. 2013 , 169, 1708-22		17
652	Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. 2013 , 23, 38-44		14
651	Inhibitory effects of a new 1H-pyrrolo[3,2-c]pyridine derivative, KIST101029, on activator protein-1 activity and neoplastic cell transformation induced by insulin-like growth factor-1. 2013 , 36, 1466-73		1
650	DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. 2013 , 6, 86-90		16

649	Mutational analysis of the , , and genes in thyroid cancer. 2013 , 6, 437-441	9
648	Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma. 2013 , 5, 1412-1416	9
647	Papillary thyroid carcinoma recurring as squamous cell carcinoma 10 years after total thyroidectomy: lessons from rapidly progressive papillary thyroid carcinoma. 2013 , 52, 1593-7	8
646	The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. 2013 , 9, 1231-41	38
645	Papillary thyroid carcinoma and variants with papillae and mimicker. 248-307	
644	Differentiated thyroid carcinoma of children and adolescents: 27-year experience in the yonsei university health system. 2013 , 28, 693-9	44
643	Multikinase inhibitors use in differentiated thyroid carcinoma. 2014 , 8, 281-91	18
642	Survivin delta Ex3 overexpression in thyroid malignancies. 2014 , 9, e100534	14
641	BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. 2014 , 9, e101354	59
640	Current status and future perspectives in differentiated thyroid cancer. 2014 , 29, 217-25	59
639	Can robotic thyroidectomy be performed safely in thyroid carcinoma patients?. 2014 , 29, 226-32	15
638	Novel therapies for thyroid cancer. 2014 , 15, 2641-52	9
637	Mouse Models of Thyroid Neoplasia: Insights into Thyroid Pathophysiology. 2014 , 1206-1222	
636	Langerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying metastatic thyroid papillary carcinoma. 2014 , 2014, 184237	8
635	Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China. 2014 , 2014, 912182	13
634	Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. 2014 , 7, 439-443	19
633	Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. 2014 , 48, 201-8	28
632	B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. 2014 , 46, e120	22

631	The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?. 2014 , 80, 899-904	41
630	Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. 2014 , 12, 979-86	73
629	Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters. 2014 , 35, 9539-48	7
628	Mutation profile of differentiated thyroid tumours in an Australian urban population. 2014 , 44, 727-34	11
627	Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis. 2014 , 42, 94-101	22
626	BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography. 2014 , 81, 432-9	21
625	Universes collide: combining immunotherapy with targeted therapy for cancer. 2014 , 4, 1377-86	62
624	BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. 2014 , 37, 1009-14	18
623	Expression and clinical significance of Shh/Gli-1 in papillary thyroid carcinoma. 2014 , 35, 10523-8	11
622	BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions. 2014 , 36, 68-73	10
621	BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. 2014 , 39, 675-9	34
620	How to use molecular testing results to guide surgery: a surgeon's perspective. 2014 , 26, 14-21	6
619	Update on the cytologic and molecular features of medullary thyroid carcinoma. 2014 , 21, 26-35	68
618	An update on clinical trials of targeted therapies in thyroid cancer. 2014 , 26, 36-44	21
617	Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. 2014 , 39, 505-10	19
616	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. 2014 , 96, e002	15
615	Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. 2014 , 2014, 638747	243
614	Role of ancillary testing in thyroid fine needle aspiration: Review and update. 2014 , 3, 218-224	1

613	Role of quantitative diffusion-weighted MRI and 1H MR spectroscopy in distinguishing between benign and malignant thyroid nodules. 2014 , 45, 89-96	3
612	Thyroid cancer. 2014 , 38, 48-74	30
611	Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model. 2014 , 24, 502-10	12
610	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. 2014 , 14, 13	182
609	BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?. 2014 , 45, 341-3	23
608	Multifocal fibrosing thyroiditis and its association with papillary thyroid carcinoma using BRAF pyrosequencing. 2014 , 25, 236-40	6
607	Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. 2014 , 46, 285-91	14
606	Molecular Markers: From Diagnosis to Prognosis in 2013. 2014 , 2, 35-43	
605	Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES). 2014 , 399, 165-84	46
604	Prognostic biomarkers in thyroid cancer. 2014 , 464, 333-46	42
603	Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology. 2014 , 25, 12-20	25
602	BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. 2014 , 45, 935-41	19
601	BRAF V600E mutational status in pediatric thyroid cancer. 2014 , 61, 1168-72	51
600	Update on the molecular diagnosis and targeted therapy of thyroid cancer. 2014 , 31, 973	8
599	The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. 2014 , 24, 1267-74	26
598	Thyroid "atypia of undetermined significance" with nuclear atypia has high rates of malignancy and BRAF mutation. 2014 , 122, 512-20	48
597	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. 2014 , 99, E1130-6	210
596	Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2014 , 21, 161-73	5.7 60

595	Thyroid nodules. 2014 , 28, 245-77		37
594	Deregulation of microRNA expression in thyroid neoplasias. 2014 , 10, 88-101		86
593	Novel approaches in anaplastic thyroid cancer therapy. 2014 , 19, 1148-55		44
592	Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. 2014 , 46, 409-16		10
591	Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. <i>Endocrine-Related Cancer</i> , 2014 , 21, 825-30	5-7	63
590	The prognostic implications from molecular testing of thyroid cancer. 2014 , 47, 595-607		8
589	New insights into the diagnosis of nodular goiter. 2014 , 7, 6		8
588	Modulation of sodium iodide symporter in thyroid cancer. 2014 , 5, 363-73		20
587	MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. 2014 , 24, 1375-84		11
586	An update on molecular biology of thyroid cancers. 2014 , 90, 233-52		68
585	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. 2014 , 23, 1527-37		13
584	Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. 2014 , 24, 1256-66		62
583	Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. 2014 , 150, 201-9		10
582	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. 2014 , 32, 2718-26		449
581	TERT and BRAF in thyroid cancer: teaming up for trouble. 2014 , 32, 2683-4		16
580	Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. 2014 , 7, 187		7
579	Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. 2014 , 7, 271		33
578	BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. 2014 , 131, 7-13		19

577	Interleukin (IL)-21 promoter polymorphism increases the risk of thyroid cancer in Chinese population. 2014 , 537, 15-9	11
576	Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. 2014 , 155, 689-95	22
575	La mutation BRAF dans le carcinome papillaire de la thyroïde : intérêt dans le pronostic à long terme et dans la radiosensibilité. 2014 , 131, 5-9	
574	Synchronous multifocal medullary and papillary thyroid microcarcinoma detected by elastography. 2014 , 5, 5-7	3
573	Molecular diagnostics for thyroid nodules: the current state of affairs. 2014 , 43, 345-65	10
572	Novel BRAF1599Ins Mutation Identified in a Follicular Variant of a Papillary Thyroid Carcinoma: A Molecular Modeling Approach. 2014 , 20, e75-9	2
571	Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. 2014 , 9, 571-577	
570	BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. 2014 , 21, 221-30	61
569	Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. 2014 , 2, 1331-1340	4
568	Role of molecular diagnostic markers in the management of indeterminate and suspicious thyroid nodules. 2014 , 1, 49-57	4
567	BRAF V600E Mutations Are Common but May Not Predict Survival in PTC. 2015 , 27, 40-42	
566	Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer. 2015 , 2, 135-142	5
565	Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. 2015 , 43, 786-90	7
564	Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. 2015 , 5, 16927	20
563	Follicular cell-derived thyroid cancer. 2015 , 1, 15077	55
562	Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. 2015 , 5, 9211	28
561	BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl. 2015 , 5, 16976	50
560	High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma. 2015 , 83, 572-80	9

559	Local molecular analysis of indeterminate thyroid nodules. 2015 , 44, 52	7
558	Genomic medicine for cancer prognosis. 2015 , 111, 31-7	
557	Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement. 2015 , 69, 14.33.1-14.33.14	2
556	Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma. 2015 , 123, 531-9	18
555	Evaluation and management of thyroid nodules with atypia/follicular lesion of undetermined significance on fine-needle aspiration. 2015 , 2, 273-289	
554	New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. 2015 , 26, 689-97	8
553	Molecular Diagnosis for Cytologically Indeterminate Thyroid Nodules. 2015 , 8, 153	1
552	Comparative Aspects of BRAF Mutations in Canine Cancers. 2015 , 2, 231-245	9
551	Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status. 2015 , 59, 364-6	2
550	Molecular Targeted Therapies of Aggressive Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2015 , 6, 176	5.7 39
549	Ultrasonography of various thyroid diseases in children and adolescents: a pictorial essay. 2015 , 16, 419-29	20
548	Ras oncogene-mediated progressive silencing of extracellular superoxide dismutase in tumorigenesis. 2015 , 2015, 780409	12
547	The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. 2015 , 2015, 642046	11
546	Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers. 2015 , 4,	4
545	The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms. 2015 , 23, 36-43	9
544	Evaluation and management of the pediatric thyroid nodule. 2015 , 20, 19-27	38
543	The management of thyroid nodules and cancer in the molecular era. 2015 , 2, 301-315	1
542	Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation. 2015 , 94, e760	14

541	ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection. 2015 , 44, 7-357	35
540	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report. 2015 , 3, 2324709615603723	2
539	Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. 2015 , 46, 1557-65	10
538	High-Resolution Melting Is a Sensitive, Cost-Effective, Time-Saving Technique for BRAF V600E Detection in Thyroid FNAB Washing Liquid: A Prospective Cohort Study. 2015 , 4, 73-81	9
537	Sonographic and cytopathologic correlation of papillary thyroid carcinoma variants. 2015 , 34, 1-15	16
536	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. 2015 , 359, 269-74	8
535	Sorafenib for the treatment of thyroid cancer: an updated review. 2015 , 16, 573-83	25
534	The status of BRAFV600E mutation among Egyptian patients with papillary thyroid carcinoma. 2015 , 24, 715-720	
533	Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis. 2015 , 106, 127-33	20
532	BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. 2015 , 4, 791-9	45
531	BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. <i>Endocrine-Related Cancer</i> , 2015 , 22, 159-68	5.7 80
530	Treatment of advanced thyroid cancer: role of molecularly targeted therapies. 2015 , 10, 311-24	16
529	Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. 2015 , 141, 1749-56	18
528	Surgeon-performed ultrasound-guided FNAC with on-site cytopathology improves adequacy and accuracy. 2015 , 125, 1633-6	10
527	Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma. 2015 , 25, 1020-5	10
526	Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. 2015 , 46, 1443-54	35
525	Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. 2015 , 22, 410-6	19
524	Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. 2015 , 158, 1500-11	30

523	Simultaneous suppression of the MAP kinase and NF- κ B pathways provides a robust therapeutic potential for thyroid cancer. 2015 , 368, 46-53	18
522	Sorafenib in the treatment of thyroid cancer. 2015 , 15, 863-74	13
521	Proteome analysis in thyroid pathology. 2015 , 12, 375-90	21
520	Epigenetic modifications in human thyroid cancer. 2015 , 3, 3-8	32
519	Lung adenocarcinoma and its thyroid metastasis characterized on fine-needle aspirates by cytomorphology, immunocytochemistry, and next-generation sequencing. 2015 , 43, 585-9	18
518	VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. 2015 , 467, 155-68	17
517	Detection of BRAF mutations on direct smears of thyroid fine-needle aspirates through cell transfer technique. 2015 , 143, 500-4	11
516	Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. 2015 , 10, 171-8	9
515	Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. 2015 , 36, 6295-304	65
514	N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. 2015 , 6, 543-7	21
513	VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases. 2015 , 143, 437-44	15
512	BRAF(V600E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis. 2015 , 35, 591-599	10
511	Reply to C. Bal et al. 2015 , 33, 2483-4	1
510	Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas. 2015 , 99, 492-7	14
509	A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma. 2015 , 26, 309-14	1
508	RAS proto-oncogene in medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2015 , 22, R235-52	5-7 64
507	Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. 2015 , 38, 1327-34	11
506	KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1. 2015 , 95, 1269-77	6

505	Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma? <i>Endocrine-Related Cancer</i> , 2015 , 22, R311-24	5-7	39
504	Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. 2015 , 157, 119-25		25
503	The evolving field of kinase inhibitors in thyroid cancer. 2015 , 93, 60-73		26
502	Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. 2015 , 137, 1001-11		32
501	The follicular variant of papillary thyroid carcinoma as a source of false negative cytopathology: a report of four cases with an emphasis on the multifocality of nuclear changes. 2015 , 43, 174-7		4
500	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. 2015 , 33, 42-50		345
499	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. 2015 , 100, E77-81		96
498	MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma. 2014 , 4, 6495		23
497	BRAFV600E Test for Suspicious Lateral Lymph Nodes in Papillary Thyroid Cancer. 2016 , 16, 36		1
496	Next-generation sequence detects a novel oncogene in papillary thyroid carcinoma. 2016 , 9, 7161-7167		7
495	Selective use of sorafenib in the treatment of thyroid cancer. 2016 , 10, 1119-31		47
494	Tumor Heterogeneity and Therapeutic Resistance. 2016 , 35, e585-93		19
493	Association between the Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population. 2016 , 7, 2420-2426		9
492	Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas. 2016 , 38, 1772-1779		3
491	Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis. 2016 , 46, 146-57		22
490	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. 2016 , 38, 249-60		20
489	Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma. 2016 , 38, 1509-14		5
488	Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies. 2016 , 117, 1491-6		6

487	c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. 2016 , 55, 1678-1687	38
486	Targeted therapies in thyroid cancer: an extensive review of the literature. 2016 , 9, 1299-1313	20
485	Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. 2016 , 124, 271-7	10
484	Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. 2016 , 239, 72-83	38
483	Correlation between polymorphisms of BRAF gene and papillary thyroid carcinoma. 2016 , 84, 431-7	
482	Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. 2016 , 129, 142-147	
481	Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. 2016 , 124, 340-9	14
480	Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. 2016 , 84, 748-55	7
479	DNA methylation analysis for the diagnosis of thyroid nodules - a pilot study with reference to BRAF(V) (600E) mutation and cytopathology results. 2016 , 27, 122-30	7
478	Advances and practical use of the molecular markers for thyroid cancer. 2016 , 4, 33948	2
477	A panel of four genes accurately differentiates benign from malignant thyroid nodules. 2016 , 35, 169	23
476	Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo. 2016 , 17, 281-291	12
475	Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines. 2016 , 36, 3673-3681	10
474	Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. 2016 , 49, 2303-2308	19
473	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. 2016 , 15, 533-47	46
472	TERT promoter mutations in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2016 , 23, R143-55	5-7 207
471	Predictive Factors for Lymph Node Metastasis in Papillary Thyroid Microcarcinoma. 2016 , 23, 2866-73	53
470	Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma. 2016 , 40, 2123-30	3

469	Ultrasound-Guided Laser Ablation Using Multidirectional-Firing Fiber for Papillary Thyroid Carcinoma: An Ex Vivo Study with Evaluation of Tumor Cell Viability. 2016 , 34, 300-4	8
468	miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. 2016 , 16, 201	22
467	Diagnostic and Prognostic Molecular Markers in Thyroid Cancer. 2016 , 281-292	1
466	Molecular Pathogenesis of Thyroid Cancer and Oncogenes in Thyroid Cancer. 2016 , 17-30	1
465	Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. 2016 , 11, 55	60
464	Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. 2016 , 17, 1353-63	4
463	B-Raf mutation and papillary thyroid carcinoma patients. 2016 , 11, 2699-2705	7
462	Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma. 2016 , 50, 38-45	11
461	Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. 2016 , 17, 1272-82	195
460	The changing incidence of thyroid cancer. 2016 , 12, 646-653	446
459	Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. 2016 , 14, 204	14
458	Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. 2016 , 16, 1303-1309	12
457	MicroRNAs in the thyroid. 2016 , 30, 603-619	31
456	Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer. 2016 , 26, 1719-1732	21
455	Molecular Aspects of Thyroid Cancer in Children. 2016 , 31-41	
454	Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas. 2016 , 54, 129-138	6
453	BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. 2016 , 11, 39	12
452	BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma. 2016 , 38 Suppl 1, E1203-9	11

451	Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. 2016 , 100, 236-41	16
450	Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung. 2016 , 11, 261-5	46
449	Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. 2016 , 26, 227-34	41
448	BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. 2016 , 54, 1531-9	12
447	MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2016 , 23, 135-46	5-7 20
446	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. 2016 , 11, 21	41
445	Thyroid Cancer. 2016 , 471-485	
444	RNA sequencing identifies crucial genes in papillary thyroid carcinoma (PTC) progression. 2016 , 100, 151-9	20
443	Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. 2016 , 26, 532-42	38
442	TERT Promoter Mutations in Thyroid Cancer. 2016 , 7, 165-77	34
441	Prophylactic Central Neck Dissection Might Not Be Necessary in Papillary Thyroid Carcinoma: Analysis of 11,569 Cases from a Single Institution. 2016 , 222, 853-64	32
440	Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. 2016 , 101, 962-71	16
439	Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer. 2016 , 26, 235-41	24
438	Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma. 2016 , 26, 404-13	39
437	IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model. 2016 , 96, 89-97	22
436	ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. 2016 , 174, R117-26	50
435	TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. 2016 , 35, 1909-18	24
434	Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies. 2016 , 37-51	

433	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2016 , 26, 1-133	6910
432	Comparison Between Real-Time PCR and Pyrosequencing for Detection of BRAF V600E Mutation in Thyroid Fine-Needle Aspirates. 2017 , 25, 358-365	4
431	TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. 2017 , 7, 41752	32
430	BRAF Mutation in a Follicular Thyroid Adenoma: A Case Report. 2017 , 25, 348-351	13
429	A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. 2017 , 6, R8-R17	45
428	Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. 2017 , 130, 86-106	15
427	The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. 2017 , 70, 260-265	17
426	Molecular Genetics of Thyroid Cancer in Children and Adolescents. 2017 , 46, 389-403	33
425	Attenuation Limits Progression of -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF Inhibitor PLX4720. 2017 , 77, 2161-2172	12
424	Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. 2017 , 16, 663-679	21
423	ZCCHC12, a novel oncogene in papillary thyroid cancer. 2017 , 143, 1679-1686	12
422	The role of molecular diagnostic testing in the management of thyroid nodules. 2017 , 17, 567-576	4
421	Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. 2017 , 9, 45	40
420	Association between BRAF mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma. 2017 , 13, 1595-1600	6
419	Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. 2017 , 64, 75-81	0
418	Quantitative NMR analysis of intra- and extracellular metabolism of mammalian cells: A tutorial. 2017 , 980, 1-24	78
417	Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1. 2017 , 8, 450-458	19
416	Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. 2017 , 40, 1235-1241	14

415	Novel treatment options for anaplastic thyroid cancer. 2017 , 12, 279-288	10
414	Zebrafish and the Cancer Moonshot. 2017 , 14, 390-392	2
413	ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW. 2017 , 23, 979-988	110
412	Cytotoxic and genotoxic effects of I and Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment. 2017 , 58, 451-461	1
411	Staging for Papillary Thyroid Cancer. 2017 , 165-185	
410	Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. 2017 , 64, 75-81	9
409	Prognostic indicators for papillary thyroid carcinoma. 2017 , 12, 101-108	4
408	Uncommon Cancers of the Thyroid. 2017 , 713-729	
407	Therapeutic effects of adenovirus-mediated CD and NIS expression combined with NaI/5-FC on human thyroid cancer. 2017 , 14, 7431-7436	2
406	BRAF mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account. 2017 , 14, 4122-4134	13
405	Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF Mutated Papillary Thyroid Cancer: Two Case Reports. 2017 , 27, 1201-1205	9
404	The Role of Chemokines in Thyroid Carcinoma. 2017 , 27, 1347-1359	29
403	Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological Studies. 2017 , 6, 178-186	31
402	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. 2017 , 13, 644-660	208
401	Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. 2017 , 29, 151-158	14
400	Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. 2017 , 14, 1439-1444	5
399	PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. 2017 , 12, 72	17
398	BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. 2017 , 7, 4666	28

397	The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. 2017 , 11, 82		10
396	Single Point Mutations in Pediatric Differentiated Thyroid Cancer. 2017 , 27, 189-196		37
395	A six-genotype genetic prognostic model for papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2017 , 24, 41-52	5:7	47
394	Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size . 2017 , 27, 207-214		6
393	Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. 2017 , 102, 634-643		38
392	Correlation of BRAF mutation and SUV levels in thyroid cancer patients incidentally detected in F-fluorodeoxyglucose positron emission tomography. 2017 , 55, 215-222		2
391	NADPH Oxidase NOX4 Is a Critical Mediator of BRAF-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. 2017 , 26, 864-877		41
390	Molecular Testing in Thyroid Cancer. 2017 , 391-399		
389	Cyclooxygenase-2 (COX-2) gene polymorphism in patients with differentiated thyroid carcinomas in the Turkish population. 2017 , 47, 1848-1853		3
388	Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer-A Review. 2017 , 18,		24
387	Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets. 2017 , 2017, 2545031		21
386	Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. 2017 , 6,		34
385	Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology. 2017 , 8, 49421-49442		32
384	Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. 2018 , 9, 305		10
383	Identification of key genes of papillary thyroid cancer using integrated bioinformatics analysis. 2018 , 41, 1237-1245		22
382	Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF Mutation in Papillary Thyroid Carcinoma. 2018 , 25, 1775-1781		21
381	EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines. 2018 , 15, 6763-6769		3
380	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. 2018 , 39, 154-191		28

379	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. 2018 , 126, 64-79	6
378	In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. 2018 , 472, 779-787	16
377	Differential expression of PIWIL2 in papillary thyroid cancers. 2018 , 649, 8-13	4
376	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. 2018 , 9, 579	89
375	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. 2018 , 110, 362-370	42
374	Management of recurrent or metastatic thyroid cancer. 2018 , 3, e000359	14
373	lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway. 2018 , 15, 5865-5870	24
372	Combined BRAF analysis and Tc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation. 2018 , 41, 1283-1288	3
371	Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. 2018 , 469, 23-37	31
370	Thyroid Nodules in Children. 2018 , 207-231	1
369	Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma. 2018 , 214, 303-307	13
368	Hypoxia Increases Thyroid Cancer Stem Cell-Enriched Side Population. 2018 , 42, 350-357	14
367	Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions. 2018 , 28, 60-67	34
366	Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. <i>Endocrine-Related Cancer</i> , 2018 , 25, R59-R82	5-7 93
365	Is BRAF V600E Mutation the Explanation for Age-Associated Mortality Risk in Patients With Papillary Thyroid Cancer?. 2018 , 36, 433-434	2
364	Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. 2018 , 36, 438-445	68
363	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. 2018 , 36, 2787-2795	38
362	BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor- κ B, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia. 2018 , 24, 6795-6808	3

361	THE ASSOCIATION BETWEEN LYMPH NODE METASTASIS AND MOLECULAR MARKERS IN DIFFERENTIATED THYROID CANCER. 2018 , 14, 55-65		2
360	Relation between RASSF1A Methylation and BRAF Mutation in Thyroid Tumor. 2018 , 11, 123		1
359	Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma. 2018 , 7, 1226-1235		11
358	Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease. 2018 , 105, 380-386		6
357	Identification of key genes and miRNAs markers of papillary thyroid cancer. 2018 , 51, 45		22
356	Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. 2018 , 14, e1007779		25
355	Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma. 2018 , 11, 7725-7731		1
354	The impact of age on thyroid cancer staging. 2018 , 25, 330-334		9
353	Active Surveillance for Papillary Thyroid Microcarcinoma: Challenges and Prospects. <i>Frontiers in Endocrinology</i> , 2018 , 9, 736	5:7	12
352	Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy. 2018 , 13, 8339-8354		20
351	The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer. 2018 , 18, 1199		13
350	TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway. 2018 , 29, 310-316		14
349	The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. 2018 , 37, 234		51
348	Integrated analysis of long noncoding RNA interactions reveals the potential role in progression of human papillary thyroid cancer. 2018 , 7, 5394-5410		13
347	The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer. 2018 , 16, e56120		7
346	Male Sex Is Associated with Increased Mortality from Papillary Thyroid Cancers with BRAF V600E Mutation. 2018 , 30, 450-452		
345	Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. 2018 , 11, 13		12
344	BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer. 2018 , 356, 130-134		10

343	Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. 2018 , 10, 646-657	4
342	Molecular testing in the diagnosis of differentiated thyroid carcinomas. 2018 , 7, S19-S29	22
341	Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low/Intermediate risk differentiated thyroid cancer. 2018 , 6, 347-355	2
340	Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study. 2018 , 10, 3237-3243	23
339	A novel tumor suppressor gene is correlated with progression in papillary thyroid carcinoma. 2018 , 11, 307-311	5
338	BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases. 2018 , 43, e215-e219	4
337	Detection of BRAF V600E Mutations With Next-Generation Sequencing in Infarcted Thyroid Carcinomas After Fine-Needle Aspiration. 2018 , 150, 177-185	3
336	GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly. 2018 , 2018, 6546832	3
335	Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. 2018 , 8, 11456	7
334	High expression and localization of E-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients. 2018 , 105, 181-189	3
333	Molecular Network-Based Identification of Competing Endogenous RNAs in Thyroid Carcinoma. 2018 , 9,	19
332	Clinical effect of and its relevance to V600E mutation in papillary thyroid carcinoma: a case-control study. 2018 , 10, 1351-1358	2
331	Can Suspicious Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Cancer?. 2018 , 7, 205-210	4
330	Co-existence of and promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. 2018 , 10, 1005-1013	25
329	LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer. 2018 , 503, 257-263	7
328	DNA methylation alterations as therapeutic prospects in thyroid cancer. 2019 , 42, 363-370	10
327	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. 2019 , 20,	39
326	MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS. 2019 , 25, 1255-1262	5

325	mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas. 2019 , 29, 1105-1114	19
324	Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. 2019 , 9, 4461-4473	62
323	Mapping Driver Mutations to Histopathological Subtypes in Papillary Thyroid Carcinoma: Applying a Deep Convolutional Neural Network. 2019 , 8,	11
322	Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. 2019 , 55, 127-135	7
321	Association of Gene Polymorphism rs3027898 With Papillary Cancer Restricted to the Thyroid Gland: A Pilot Study. 2019 , 33, 2281-2285	0
320	IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma. 2019 , 104, 5573-5584	8
319	BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. 2019 , 411, 1085-1094	2
318	Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression. 2019 , 18, 3227-3235	7
317	Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance. 2019 , 18, 2819-2824	3
316	Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario. <i>Frontiers in Endocrinology</i> , 2019 , 10, 552	5-7 15
315	Radiation-Induced Thyroid Cancers: Overview of Molecular Signatures. 2019 , 11,	12
314	The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration. 2019 , 30, 312-317	3
313	Personalized treatment options for thyroid cancer: current perspectives. 2019 , 12, 235-245	9
312	Discrimination of the Mutation in by Rolling Circle Amplification and Förster Resonance Energy Transfer. 2019 , 4, 2786-2793	7
311	BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. 2019 , 11,	33
310	Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. 2019 , 4, 37-49	3
309	Genetic-guided Risk Assessment and Management of Thyroid Cancer. 2019 , 48, 109-124	26
308	Key candidate genes associated with BRAF in papillary thyroid carcinoma on microarray analysis. 2019 , 234, 23369-23378	10

307	IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma. 2019 , 9, 44	13
306	The significance of gene mutations across eight major cancer types. 2019 , 781, 88-99	8
305	Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. 2019 , 457, 129-141	9
304	Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing. 2019 , 99, 587-598	5
303	Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer. 2019 , 17, 4661-4666	6
302	The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology. 2019 , 30, 460-467	5
301	Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma. 2019 , 41, 2602-2609	6
300	BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases. 2019 , 223, 166-173	6
299	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking. 2019 , 98, 652-658	11
298	Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. 2019 , 16, 450-460	91
297	Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation. 2019 , 17, 12	4
296	Crosstalk between Metabolic Alterations and Altered Redox Balance in PTC-Derived Cell Lines. 2019 , 9,	5
295	BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma. 2019 , 12, 1465-1473	4
294	Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR. 2019 , 215, 761-765	1
293	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. 2019 , 29, 523-529	19
292	Generation and identification of a thyroid cancer cell line with stable expression of CCDC67 and luciferase reporter genes. 2019 , 18, 4495-4502	
291	The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma. 2019 , 11, 5071-5078	7
290	Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma. 2019 , 2019, 2315673	1

289	Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: two case reports and review of the literature. 2019 , 13, 385	8
288	Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer. 2019 , 19, 1260	13
287	Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas. 2019 , 11,	11
286	JAZF1 Suppresses Papillary Thyroid Carcinoma Cell Proliferation and Facilitates Apoptosis via Regulating TAK1/NF- κ B Pathways. 2019 , 12, 10501-10514	8
285	Downregulation of CDH16 in Papillary Thyroid Cancer and Its Potential Molecular Mechanism Analysed by qRT-PCR, TCGA and in silico Analysis. 2019 , 11, 10719-10729	4
284	Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. 2019 , 104, 258-265	28
283	Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells. 2019 , 35, 2267-2275	18
282	Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis. 2019 , 45, 1018-1024	6
281	The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?. 2019 , 40, 8-13	4
280	Molecular Genetics and Diagnostics of Thyroid Cancer. 2019 , 549-561	
279	Epidemiology of Thyroid Cancer. 2019 , 541-547	3
278	Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome. 2019 , 104, 103-110	13
277	Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. 2019 , 63, 94-100	9
276	Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population. 2020 , 26, 347-354	11
275	Management of Undifferentiated (Anaplastic) Thyroid Cancer. 2020 , 27-34	1
274	Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?. 2020 , 502, 110676	2
273	Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. 2020 , 26, 1833-1841	3
272	Adolescents with thyroid nodules: retrospective analysis of factors predicting malignancy. 2020 , 179, 317-325	4

271	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. 2020 , 124, 161-169	24
270	BRAF molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics. 2020 , 128, 9-11	0
269	SOX18 exerts tumor-suppressive functions in papillary thyroid carcinoma through inhibition of Wnt/ β -catenin signaling. 2020 , 396, 112249	4
268	The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. 2020 , 532, 315-320	4
267	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. 2020 , 156, 103119	31
266	BRAF: A Two-Faced Janus. 2020 , 9,	10
265	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. 2020 , 79, 180-180	25
264	Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. 2020 , 12,	22
263	Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. 2020 , 12,	9
262	Predictive factors of contralateral occult carcinoma in patients with papillary thyroid carcinoma: a retrospective study. 2020 , 9, 872-878	2
261	CYP2S1 is a synthetic lethal target in BRAF-driven thyroid cancers. 2020 , 5, 191	5
260	Alterations of regulatory factors and DNA methylation pattern in thyroid cancer. 2020 , 28, 255-268	10
259	Identification and validation of mA RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. 2020 , 20, 203	23
258	Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma. 2020 , 216, 153037	3
257	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. 2020 ,	4
256	Regulators of glucose uptake in thyroid cancer cell lines. 2020 , 18, 83	16
255	Ultrasound validation of predictive model for central cervical lymph node metastasis in papillary thyroid cancer on. 2020 , 16, 1607-1618	2
254	Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel. 2020 , 105,	10

253	Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. 2020 , 12,	7
252	Challenging diagnosis of two neoplasms, Langerhans cell histiocytosis and papillary thyroid carcinoma, from fine needle aspiration of the thyroid by cell-block immunocytochemistry and molecular testing for BRAF V600E mutation. 2020 , 31, 598-601	2
251	Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia. <i>Frontiers in Endocrinology</i> , 2020 , 11, 146	5-7 1
250	Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer. 2020 , 21, 18	6
249	A protein-centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes. 2020 , 41, 934-945	0
248	Solid variant of papillary thyroid carcinoma: an under-recognized entity. 2020 , 67, 241-248	3
247	Novel treatments for anaplastic thyroid carcinoma. 2020 , 9, S28-S42	32
246	Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition. 2020 , 38, 158-166	3
245	An Animal Model Further Uncovers the Role of Mutant Braf during Papillary Thyroid Cancer Development. 2020 , 190, 702-710	1
244	Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition. 2020 , 52, 116-124	4
243	Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF mutation as biomarkers for papillary thyroid carcinoma. 2020 , 235, 6954-6968	10
242	Preparation and SPECT/CT Imaging of Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice. 2020 , 13, 487-496	1
241	Radiomics Study of Thyroid Ultrasound for Predicting Mutation in Papillary Thyroid Carcinoma: Preliminary Results. 2020 , 41, 700-705	8
240	Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?. 2020 , 12,	8
239	BRAF Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. 2020 , 44, 2685-2691	14
238	BRAF and TERT promoter mutations: clinical application in thyroid cancer. 2020 , 67, 577-584	5
237	Correlation between telomerase reverse transcriptase messenger RNA expression and survival of patients with papillary thyroid carcinoma. 2021 , 169, 43-49	1
236	Thyroid and Parathyroid Glands. 2021 , 606-688	

235	Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy. 2021 , 71, 418-426	3
234	BRAF Overrides NOTCH Signaling in Thyroid Cancer. 2021 , 31, 787-799	3
233	VE1 immunohistochemistry is an adjunct tool for detection of BRAF mutation: Validation in thyroid cancer patients. 2021 , 35, e23628	5
232	Preoperative Typing of Thyroid and Parathyroid Tumors with a Combined Molecular Classifier. 2021 , 13,	2
231	Modern approaches to the treatment of radioiodine-refractory differentiated thyroid cancer. 2021 , 12, 35-48	
230	KRAS/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis. 2021 , 27, 539-546	5
229	Thyroid Cancer and SNPs. 2021 , 235-280	
228	A Real-World Study of Factors Associated with Postoperative Recurrence of Papillary Thyroid Carcinoma. 2021 , 11, 357-365	
227	Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. 2020 , 10, 544579	0
226	Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. 2021 , 11, 6251-6277	10
225	Prognostic Assessment of BRAF Mutation in Preoperative Thyroid Fine-Needle Aspiration Specimens. 2021 , 156, 100-108	0
224	The Role of Intrinsic Signaling Pathways in Cell Proliferation. 2021 , 11, 2030003	1
223	BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer. 2021 , 42, 611-618	1
222	Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. 2021 , 13,	3
221	The clonal origin of multifocal papillary thyroid cancer: intrathyroidal spread or independent tumors?. 2021 , 46, 35-44	3
220	Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience. 2021 , 10, 155-163	1
219	Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. 2021 , 32, 44-62	5
218	Upregulation of TRIB2 by Wnt/ β -catenin activation in BRAF papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib. 2021 , 88, 155-164	3

217	Improving the diagnosis of AUS/FLUS thyroid nodules using an algorithm with combination of BRAFV600E mutation analysis and ultrasound pattern-based risk stratification. 2021 , 77, 273-285	1
216	LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/ β catenin signaling pathway and epithelial-mesenchymal transition. 2021 , 21, 442	4
215	Prospective Analysis of Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution. 2021 , 10,	0
214	Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. 2021 , 13,	2
213	The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and Mutation. 2021 , 14, 3959-3969	0
212	How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis. 2021 , 129, 819-829	2
211	Proposal of a New Prognostic Model for Differentiated Thyroid Cancer with Promoter Mutations. 2021 , 13,	2
210	β Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF-Driven Thyroid Cancer Animal Model. 2021 , 20, 1603-1613	
209	Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas. 2021 , 95, 790-799	0
208	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. 2021 , 106, 3228-3238	8
207	and Thyroid Tumors. 2021 , 13,	0
206	The Role of Vitamin D as a Prognostic Marker in Papillary Thyroid Cancer. 2021 , 13,	3
205	Tumor invasive ability of papillary thyroid carcinomas is not conferred by acquired gene mutations. 2021 , 69, 1382-1385	
204	Computer-assisted image analysis of cytological specimens clarify the correlation between nuclear size and intranuclear cytoplasmic inclusions regardless of BRAFV600E mutation in papillary thyroid carcinoma. 2021 , 32, 718-731	
203	The Emerging Landscapes of Long Noncoding RNA in Thyroid Carcinoma: Biological Functions and Clinical Significance. 2021 , 11, 706011	3
202	Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development. 2022 , 15,	0
201	The emerging role of transcription factor FOXP3 in thyroid cancer. 2021 , 1	0
200	Systemic Therapy in Thyroid Cancer.. 2022 , 13, 68-80	

199	Looking at the BiG picture: Incorporating bipartite graphs in drug response prediction.	0
198	Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma. 2021 , 14,	1
197	Analysis of and somatic mutations in differentiated thyroid cancers. 2021 , 15, 210	1
196	The relationship between autophagy-related genes and the staging and prognosis of thyroid cancer: a bioinformatics analysis. 2021 , 10, 2511-2527	1
195	Platelet-Derived Growth Factor Receptor- β Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer and. 2021 , 29, 551-561	3
194	BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules. 2021 , 100, e27167	1
193	Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. 2021 ,	2
192	Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. 2021 , 30, 913-921	0
191	Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer. 2021 , 131,	1
190	MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2. 2021 , 21, 494	3
189	Role of Advanced Glycation End-Products and Other Ligands for AGE Receptors in Thyroid Cancer Progression. 2021 , 10,	1
188	Combined targeted therapy and immunotherapy for cancer treatment. 2021 , 9, 7643-7652	0
187	Epigenetic Silencing of SOX15 Is Controlled by miRNAs rather than Methylation in Papillary Thyroid Cancer. 2021 , 2021, 1588220	
186	A new risk factor indicator for papillary thyroid cancer based on immune infiltration. 2021 , 12, 51	10
185	Pediatric Surgical Pathology of the Thyroid and Parathyroid. 2021 , 447-469	
184	Carcinogenesis and Therapeutic Strategies for Thyroid Cancer. 2009 , 347-374	1
183	The biology of thyroid oncogenesis. 2010 , 153, 3-21	6
182	Molecular Profiles and the Indeterminate Thyroid Nodule. 2016 , 143-156	1

181	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. 2017 , 545-583	1
180	Schilddrüse. 2016 , 631-712	3
179	Thyroid Pathology. 2012 , 59-93	1
178	Cancer of the Thyroid. 2010 , 726-736	1
177	EVIDENCE OF A LOW PREVALENCE OF RAS MUTATIONS IN A LARGE MEDULLARY THYROID CANCER SERIES. 120822105920003	3
176	The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. 2018 , 24, 3002-3010	12
175	Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. 2014 , 9, e110868	15
174	BRAF Mutations in Canine Cancers. 2015 , 10, e0129534	61
173	Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. 2016 , 11, e0159235	9
172	Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy. 2019 , 8, 754-763	10
171	Clinical prognosis in BRAF-mutated PTC. 2007 , 51, 736-47	15
170	BRAF mutation in the elderly submitted to thyroidectomy. 2013 , 40, 110-6	1
169	is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression. 2020 , 12, 16437-16456	8
168	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. 2017 , 8, 583-595	16
167	Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. 2017 , 8, 900-914	8
166	Clinical value and indication for the dissection of lymph nodes posterior to the right recurrent laryngeal nerve in papillary thyroid carcinoma. 2017 , 8, 79897-79905	9
165	The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. 2010 , 1, 751-756	42
164	PIK3CA-induced paradoxical ERK activation results in resistance to BRAF specific inhibitors in BRAF PIK3CA double mutant thyroid tumors. 2017 , 8, 103207-103222	10

163	Melanoma patients with additional primary cancers: a single-center retrospective analysis. 2019 , 10, 3373-3384	1
162	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. 2015 , 6, 21993-2005	19
161	REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. 2015 , 6, 39211-24	20
160	Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. 2016 , 7, 40792-40799	43
159	Clinical and Translational Challenges in Thyroid Cancer. 2020 , 27, 4806-4822	2
158	Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. 2011 , 12, 609-17	61
157	Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. 2014 , 15, 171-7	12
156	Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer. 2014 , 15, 184-9	6
155	Personalization of targeted therapy in advanced thyroid cancer. 2014 , 15, 190-202	14
154	Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma. 2019 , 14, 290-298	4
153	Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital. 2020 , 21, 3267-3277	2
152	Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. 2012 , 35, 413-8	15
151	Papillary thyroid cancer and inflammatory bowel disease: is there a relationship?. 2013 , 19, 1079-84	6
150	Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. 2019 , 34, 215-225	23
149	Prognostic implications of the BRAF-V600 mutation in papillary thyroid carcinoma based on a new cut-off age stratification. 2020 , 19, 631-640	9
148	Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer. 2017 , 32, 780-789	6
147	Prevalence of BRAFV600E Mutation in Iranian Patients with Papillary Thyroid Carcinoma: A Single-Center Study. 2009 , 9, 3593-3597	6
146	BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. 2013 , 2, 244-50	36

145	Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield. 2017 , 14, 4	13
144	Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens. 2016 , 50, 58-66	9
143	The Significance of TROP2 Expression in Predicting Mutations in Papillary Thyroid Carcinoma. 2018 , 52, 14-20	8
142	Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma. 2009 , 43, 495	2
141	The Frequency of BRAF Mutation in Very Small Papillary Thyroid Carcinomas. 2010 , 44, 308	3
140	TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer. 2016 , 48, 942-7	14
139	Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF Mutation. 2017 , 9, 185-193	7
138	BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review. 2015 , 32, 156-66	14
137	Recent progress of genome study for anaplastic thyroid cancer. 2013 , 11, 68-75	22
136	The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. 2009 , 133, 803-5	20
135	Thyroid-type carcinoma of struma ovarii. 2010 , 134, 786-91	49
134	Molecular diagnostics of thyroid tumors. 2011 , 135, 569-77	176
133	Development of a Molecular Assay for Detection and Quantification of the BRAF Variation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens. 2021 , 4, e2127243	0
132	Construction and Evaluation of a Tumor Mutation Burden-Related Prognostic Signature for Thyroid Carcinoma. 2021 , 2021, 1435827	
131	The significant increase of miR-140-5P in papillary thyroid cancer samples. 2021 , 25, 101391	
130	The Multiple Endocrine Neoplasia Syndromes. 2009 , 931-944	
129	Molecular Biology of Thyroid Cancer. 2009 , 97-110	
128	Molecular Cytopathology. 2009 , 167-180	0

- 127 Combinatorial Targeted Therapy in Thyroid Cancer. **2010**, 53, 203
- 126 Carcinoma della tiroide. **2011**, 403-420
- 125 Imaging and Clinical Features of Thyroid Cancer in Children and Adolescents. **2011**, 65, 181
- 124 Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer. **2011**, 27-38
- 123 Thyroid Pathology. **2012**, 269-312
- 122 Fine-Needle Aspiration Cytology of the Thyroid. **2012**, 77-106
- 121 Genes and Nevogenesis. **2012**, 127-135
- 120 Thyroid Cancer. **2012**, 61-91
- 119 Pancreatic metastasis arising from a a BRAFV600E-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. 120214230723006
- 118 Thyroid Cancer: Molecular Genetics.
- 117 Molecular Pathology of Endocrine Cancer. **2013**, 407-423
- 116 Usefulness of Molecular Biology in Follicular-Derived Thyroid Tumors: From Translational Research to Clinical Practice. **2013**, 391-428
- 115 Gene Methylation Associated with Differentiated Thyroid Cancer. **2014**, 7, 118
- 114 Risk-Adjusted Strategies in Post-Treatment Surveillance of Well-Differentiated Thyroid Carcinoma. **2015**, 79-92
- 113 Evaluation of Pyrosequencing Method for a BRAFV600E Mutation Test. **2015**, 47, 17-23 1
- 112 Undifferentiated Thyroid Carcinoma. **2016**, 8-44-8-47
- 111 Potential Approaches to Chemotherapy of Thyroid Cancer in the Future. **2016**, 1001-1006
- 110 Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. **2016**, 1-40 1

- 109 Etiopathogenesis of Differentiated Thyroid Carcinomas. **2016**, 4, 517-522 5
- 108 Examination History and Abnormal Thyroid and Breast Lesions According to Residential Distance from Nuclear Power Plants. **2016**, 41, 402-408
- 107 Cancer Genetics at a Glance: The Comprehensive Insights. **2017**, 79-389 1
- 106 [BRAF-positive paucicellular variant of anaplastic carcinoma in the presence of tall cell variant papillary thyroid cancer]. **2017**, 79, 27-33
- 105 Clinical Characteristics and Prognosis of Differentiated Thyroid Carcinoma with Small Foci of Anaplastic Transformation. **2017**, 10, 96
- 104 Molecular Aspects of Thyroid Carcinogenesis. **2017**, 175-184
- 103 Local and Systemic Treatment of Unresectable Disease. **2017**, 263-280
- 102 BRAF MUTATION ANALYSIS IN THYROID DISEASES- A STUDY FROM A TERTIARY CARE HOSPITAL/CENTRE IN KERALA. **2017**, 6, 3359-3361
- 101 Oncoplastic Thyroid Surgery Using A Bilateral Axillo-Breast Approach. **2017**, 20, 51-57
- 100 PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.
- 99 Thyroid and Parathyroid Glands. **2018**, 85-141
- 98 Management of Distant Metastasis in Differentiated Thyroid Cancer. **2018**, 121-140
- 97 Targeted Molecular Therapy. **2019**, 647-654 2
- 96 In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies. **2019**, 16, 570-583 1
- 95 A protein-centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes.
- 94 GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer. **2019**, 10, 4107-4124 2
- 93 Network-Based Analysis Reveals Association of FOXE1 Gene Polymorphisms in Thyroid Cancer Patients; A Case-Control Study in Southeast of Iran. **2020**, 21, 2771-2776 0
- 92 Whole-Exome Sequencing in Papillary Microcarcinoma: Potential Early Biomarkers of Lateral Lymph Node Metastasis. **2021**, 36, 1086-1094 0

91	Synergistic effect of metformin and vemurafenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study. 2021 , 48, 7443-7456	2
90	The Relationship between BRAF V600E Mutation and the Clinicopathological Features of the Papillary Thyroid Carcinoma. 2020 , 11, 216-227	
89	BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results. 2020 , 9, 1902-1913	0
88	Curcumin induces autophagic cell death in human thyroid cancer cells. 2022 , 78, 105254	4
87	[Molecular markers as risk factors for thyroid cancer]. 2019 , 91, 119-123	
86	A Rare Case of Non-Small Cell Lung Cancer with BRAF V600E Gene: Case Report and Literature Review. 2020 , 12, e7055	1
85	Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH-TSHR pathway in anaplastic thyroid carcinoma cells. 2021 ,	0
84	BRAF V600E mutation in papillary thyroid carcinoma: it's relation to clinical features and oncologic outcomes in a single cancer centre experience. 2021 , 10, 1531-1537	2
83	BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm. 2021 , 50, 63	2
82	Thyroid cancer: retrospective study of patients with surgical treatment (a single-center experience). 2020 , 283-288	
81	BRAFV600E Test for Suspicious Lateral Lymph Nodes in Papillary Thyroid Cancer. 2016 , 16, 36	
80	Somatic Genomic Changes in the Formation of Differentiated Thyroid Carcinoma. 2020 , 47, 53-60	
79	The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. 2013 , 2, 206-11	5
78	The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. 2010 , 1, 751-6	22
77	Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. 2012 , 37, 335-56	32
76	Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma. 2015 , 8, 560-8	29
75	Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. 2015 , 8, 15072-8	11
74	A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway. 2018 , 8, 1847-1855	5

73	A Review of Driver Genetic Alterations in Thyroid Cancers. 2018 , 13, 125-135	5
72	Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression. 2019 , 11, 1760-1770	6
71	Melanoma and Thyroid Carcinoma: Our Current Understanding. 2019 , 12, 39-41	2
70	Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer. 2020 , 12, 3057-3067	2
69	The Effect of BRAF Mutation on Lymph Node Involvement in Papillary Thyroid Cancer. 2020 , 36, 249-255	1
68	Preliminary Study on the Relationship of Mutations with the Outcome of the First I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma. 2021 , 14, 8981-8989	
67	Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with -Mutant Advanced Papillary Thyroid Carcinoma. 2021 , 13,	2
66	Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report. 2021 ,	0
65	The Effect of BRAF V600E Mutation on Lymph Node Involvement in Papillary Thyroid Cancer. 2020 , 36, 249-255	1
64	Molecular Mechanisms of Glucose Uptake Regulation in Thyroid Cancer.	0
63	Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant.. 2022 , 11, 56-66	
62	Identification of prognostic signature with seven LncRNAs for papillary thyroid carcinoma.. 2022 , 67, 103-113	1
61	Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer.. 2022 , 37, 53-61	
60	Genetica del carcinoma anaplastico della tiroide. 2022 , 23, 208-211	
59	Preoperative comprehensive malignancy risk estimation for thyroid nodules: Development and verification of a network-based prediction model.. 2022 ,	
58	Major Vault Protein (MVP) Associated With Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer MAPK/ERK and PI3K/AKT Pathways.. 2021 , 9, 688370	1
57	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016).. 2022 , 12, 853076	0
56	The Treatment of Thyroid Cancer With Radiofrequency Ablation.. 2022 , 25, 100825	1

- 55 Preoperative Prediction of Central Cervical Lymph Node Metastasis in Fine-Needle Aspiration Reporting Suspicious Papillary Thyroid Cancer or Papillary Thyroid Cancer Without Lateral Neck Metastasis.. **2022**, 12, 712723 1
- 54 Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF Mutation: An Experimental Study.. **2022**,
- 53 Diagnostic value of thyroid imaging reporting and data system combined with BRAF mutation analysis in Bethesda categories III-V thyroid nodules.. **2022**, 12, 5934 0
- 52 Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.. **2022**, 157, 111121 1
- 51 Variations in kinase gladiators and risk of differentiated thyroid carcinoma.. **2022**, 16, 45
- 50 Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E. **2013**, 36, 1099-104 10
- 49 Diagnostic strategy of fine needle aspiration cytology of cystic cervical lymph node metastasis from papillary thyroid carcinoma.. **2022**,
- 48 Cathepsin F genetic mutation Is associated with familial papillary thyroid cancer.. **2022**,
- 47 The thyroid gland. 2899-2950
- 46 Table_1.pdf. **2020**,
- 45 Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. **2022**, 1-40
- 44 Induction of BRAFV600E Mutation in Thyroid Cells Leads to Frequent Hypermethylation.. **2022**, 1
- 43 Novel Therapeutics for Advanced Differentiated Thyroid Cancer. **2022**,
- 42 Papillary thyroid cancer and a TERT promotor mutation-positive paraganglioma in a patient with a germline SDHB mutation.
- 41 E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers.. **2022**, 188736 2
- 40 Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. **2022**, 58, 666 0
- 39 Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. **2022**, 23, 5731 1
- 38 The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells. **2022**, 39, 0

37	The Iodine Rush: Over- or Under-Iodination Risk in the Prophylactic Use of Iodine for Thyroid Blocking in the Event of a Nuclear Disaster. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7	0
36	How Surface-Enhanced Raman Spectroscopy Could Contribute to Medical Diagnoses. 2022 , 10, 190		0
35	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. 2022 , 14, 24113-24121		1
34	Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma. 2022 , 2022, 1-13		1
33	Predictive Factors Indicative of Hemithyroidectomy and Close Follow-Up versus Bilateral Total Thyroidectomy for Aggressive Variants of Papillary Thyroid Cancer. 2022 , 14, 2757		0
32	The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population. 2022 , 2022, 1-7		0
31	Looking at the BiG picture: incorporating bipartite graphs in drug response prediction.		0
30	Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas. 2022 , 14, 3079		0
29	Genetic Changes in Thyroid Cancers and the Importance of Their Preoperative Detection in Relation to the General Treatment and Determination of the Extent of Surgical Intervention. Review. 2022 , 10, 1515		0
28	La résistance aux inhibiteurs de BRAF. 2022 , 38, 570-578		
27	LncRNA H19 is a potential biomarker and correlated with immune infiltration in thyroid carcinoma. <i>Clinical and Experimental Medicine</i> ,	4.9	0
26	Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects. <i>Frontiers in Endocrinology</i> , 13,	5.7	2
25	Patient with multiple genetically distinct thyroid nodules including papillary thyroid carcinoma harboring novel YWHAG-BRAF fusion. <i>Cancer Genetics</i> , 2022 , 266-267, 51-56	2.3	0
24	Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer. 9,		0
23	Hashimoto's Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas. 2022 , 10, 2051		1
22	Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report. 13,		
21	Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.		0
20	Preoperative BRAF V600E mutation detection in thyroid carcinoma by immunocytochemistry.		

- 19 Zebrafish as an emerging tool for drug discovery and development for thyroid diseases. **2022**, 130, 53-60 ○
- 18 Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer. **2022**, 97-134 ○
- 17 Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. **2022**, 643-682 ○
- 16 The combination of BRAFV600E mutation and Chinese Thyroid Imaging Reporting and Data System is helpful in the management of AUS/FLUS thyroid nodules. ○
- 15 Analysis of thyroid involvement in children and adult Langerhans cell histiocytosis: An underestimated endocrine manifestation. 13, ○
- 14 Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology. 13, ○
- 13 Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases. 13, ○
- 12 High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules. ○
- 11 Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis. **2023**, 152, 106377 ○
- 10 Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study. ○
- 9 Development of Novel Murine BRAFV600E-Driven Papillary Thyroid Cancer Cell Lines for Modeling of Disease Progression and Preclinical Evaluation of Therapeutics. **2023**, 15, 879 ○
- 8 Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways. **2023**, 24, 3418 ○
- 7 Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype. 14, ○
- 6 Significance of FNAC , BRAF mutation, and intraoperative frozen section in surgical decision-making of thyroid nodules. ○
- 5 Next-Generation sequencing genomic landscape of Chinese thyroid tumors. ○
- 4 Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF / MEK signaling. ○
- 3 Less is more meets do more with less : Exploring differences in thyroid FNA molecular testing between Asian and Western practices. ○
- 2 P53 expression in cytology samples may represent a marker of early-stage cancer. ○

- 1 Synchronous thyroid cancer and malignant struma ovarii: concordant mutations and microRNA profile, discordant loss of heterozygosity loci. **2023**, 18,

o